CNMD Financials Conmed Corp

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 30 h ago Overview →

Growth & profitability

Revenue has grown 9.8% per year over the past 5 years.
Net income has grown faster than revenue (37.7% vs 9.8% per year).
Operating margin has expanded, at 7.5% in the latest year.
Free cash flow has grown 24.0% per year over the past 5 years.

Financial health

Total debt has grown faster than revenue (16.2% vs 9.8% per year).
Operating income covered interest expense 3.3× in the latest year, up from 1.0× 5 years ago.

Shareholder returns

Dividends have been paid for 14 consecutive years, consuming 52.5% of earnings and 16.4% of free cash flow.
The dividend has grown 1.6% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$1.4B	$47M	54.6%	7.5%	$151M	—	$41M
2024	$1.3B	$132M	56.1%	15.3%	$154M	—	$24M
2023	$1.2B	$65M	54.3%	9.7%	$106M	—	$24M
2022	$1.0B	-$81M	54.6%	6.7%	$12M	—	$29M
2021	$1.0B	$63M	56.2%	10.9%	$97M	—	$21M
2020	$862M	$10M	53.4%	5.3%	$52M	—	$27M
2019	$955M	$29M	54.9%	8.3%	$75M	—	$26M
2018	$860M	$41M	54.6%	8.3%	$58M	$457M	$18M
2017	$796M	$55M	54.1%	5.9%	$53M	$486M	$33M
2016	$764M	$15M	53.5%	4.9%	$25M	$498M	—
2015	—	$30M	—	—	$36M	$271M	—
2014	—	$32M	—	—	$50M	$241M	—
2013	—	$36M	—	—	$63M	$216M	—
2012	—	$40M	—	—	$74M	$162M	—
2011	—	$752000	—	—	$85M	$144M	—

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Dec '25	$373M	$17M	58.5%	9.8%	$41M	—	$41M
Sep '25	$338M	$3M	49.2%	3.5%	$48M	—	$39M
Jun '25	$342M	$21M	55.0%	11.1%	$23M	—	$34M
Mar '25	$321M	$6M	55.3%	5.0%	$38M	—	$35M
Dec '24	$346M	$34M	57.3%	15.2%	$39M	—	$24M
Sep '24	$317M	$49M	56.5%	20.7%	$48M	—	$38M
Jun '24	$332M	$30M	55.3%	14.2%	$40M	—	$29M
Mar '24	$312M	$20M	55.1%	11.2%	$27M	—	$34M
Dec '23	$327M	$33M	55.7%	15.3%	$52M	—	$24M
Sep '23	$305M	$16M	55.2%	9.9%	$41M	—	$31M
Jun '23	$318M	$14M	53.7%	8.6%	$22M	—	$28M
Mar '23	$295M	$2M	52.6%	4.3%	-$8M	—	$26M
Dec '22	$251M	$27M	52.6%	-0.4%	-$17M	—	$29M
Sep '22	$275M	$46M	55.1%	8.8%	$19M	—	$33M
Jun '22	$277M	-$168M	54.8%	8.8%	$13M	—	$53M
Mar '22	$242M	$15M	56.1%	9.3%	-$3M	—	$25M
Dec '21	$274M	$24M	56.9%	13.6%	$31M	—	$21M
Sep '21	$249M	$15M	57.2%	10.7%	$16M	—	$32M
Jun '21	$255M	$13M	55.4%	10.1%	$31M	—	$46M
Mar '21	$233M	$10M	55.2%	8.6%	$19M	—	$37M

Valuation over time

How the market has priced CNMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 42.6× (Jan '24) to 22.6× (Jun '26).
The price-to-sales ratio has fallen from 3.1× (Mar '23) to 0.8× (Jun '26).
The dividend yield has risen from 0.7% (Mar '23) to 2.3% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is CNMD growing its revenue and profit?

Over the past 5 years, Conmed Corp's revenue has grown 9.8% per year, and net income grown 37.7% per year. These are computed facts, not advice.

How much debt does CNMD have?

As of FY2025, Conmed Corp reported — of total debt against $41M of cash; operating income covered interest expense 3.3×.

What is CNMD's profit margin?

In FY2025, gross margin was 54.6%, operating margin 7.5%, and net margin 3.4%.

What is CNMD's P/E ratio?

As of Jun '26, Conmed Corp traded at a price-to-earnings ratio of about 22.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.